Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "Global Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology Clinics) - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering.
The Diabetic Macular Edema Treatment Market size was estimated at USD 2.97 billion in 2023, USD 3.12 billion in 2024, and is expected to grow at a CAGR of 5.11% to reach USD 4.22 billion by 2030. 
Key trends driving the market include the refinements in pharmacological treatments, the increasing reliance on corticosteroid injections, and advances in laser treatment modalities. Industry reports suggest a significant portion of growth is stemming from the expanding infrastructure of ophthalmology clinics and the evolving landscape of hospital care.
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetic Macular Edema Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Diabetic Macular Edema Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Aerpio Pharmaceuticals, Alcon Vision LLC, Alimera Sciences, Inc., Arctic Vision, Bausch & Lomb Incorporated, Chugai Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Graybug Vision, Inc., KalVista Pharmaceuticals, Inc., Kodiak Sciences Inc, Kubota Pharmaceutical Holdings Co. Ltd., Novartis AG, Ocugen Inc., Oculis Holding AG, Ocuphire Pharma, Inc., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd., and YD Life Science.
Market Segmentation & Coverage
This research report categorizes the Diabetic Macular Edema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Treatment
- Corticosteroid Injections
- Drugs
- Laser Treatment
- Pharmacological Treatment
- End-User
- Hospitals
- Ophthalmology Clinics
For more information about this report visit https://www.researchandmarkets.com/r/tqjrru
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
